- Alkem Laboratories reported an 11.8% YoY decline in Q2FY27 net profit to Rs 675 crore
- Revenue from operations rose 13.8% YoY to Rs 4,552 crore in Q2FY27
- EBITDA increased 11.3% YoY to Rs 1,025 crore in Q2FY27
Pharmaceutical major Alkem Laboratories reported an 11.8% year-on-year (YoY) decline in consolidated net profit to Rs 675 crore in the September quarter of financial year 2027 (Q2FY27), as against Rs 765 crore in the corresponding quarter last year.
Revenue from operations, however, increased 13.8% YoY to Rs 4,552 crore in Q2FY27, compared with Rs 4,001 crore a year ago.
At the operating front, earnings before interest, tax, depreciation and amortisation (EBITDA) rose 11.3% annually to Rs 1,025 crore in Q2FY27, from Rs 921 crore a year ago.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
EBITDA margin contracted to 22.5% from 23% a year ago. The company also reported a one-time gain of Rs 35 crore during the quarter.
The company also roped in Gopal Kothari as chief financial officer (CFO), effective December 2, 2026.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
